CD274 and esophageal squamous cell carcinoma: These data may support the inclusion of Japanese patients in ongoing pivotal global phase III studies of tiragolumab, including: SKYSCRAPER-01 (NCT04294810) in patients with advanced PD-L1-positive NSCLC, SKYSCRAPER-03 (NCT04513925) in patients with locally advanced, unresectable stage III NSCLC, SKYSCRAPER-06 (NCT04619797) in patients with previously untreated advanced non-squamous NSCLC, and SKYSCRAPER-07 (NCT04543617) in patients with unresectable esophageal squamous cell carcinoma.